Specialty hub

Haematology

Containing dedicated Learning Zones, guidelines, trials and news for related conditions in Haematology.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Haematology is the branch of medicine that deals with disorders or abnormalities in the blood and connected areas such as blood cells, haemoglobin and blood vessels. Haematology also covers bone marrow and spleen, which are the blood producing organs.

Featured Learning Zones

Cancer-Associated Thrombosis Learning Zone

Cancer‐associated thrombosis (CAT) is a frequent, potentially life‐threatening event that complicates cancer management. New treatments, including DOACs, are now recommended for CAT

Learn more

Haematology focuses on the study, diagnosis, treatment, and prevention of diseases including coagulation and haemorrhagic disorders such as fibrinogen deficiency, haematological and bone marrow cancers such as leukaemia and lymphoma, and anaemia.

Diseases in this section

Coagulation and Haemorrhagic Disorders

Containing relevant Learning Zones, guidelines, trials and news.

Haematological and Bone Marrow Cancers

Containing relevant Learning Zones, guidelines, trials and news.

HIV / AIDS

Containing relevant Learning Zones, guidelines, trials and news.

Venous thromboembolism

Containing relevant Learning Zones, guidelines, trials and news.

Related news and insights

News

Gilead + Merck announce agreement to jointly develop and commercialize long-acting, investigational treatment combinations of lenacapavir and islatravir in HIV.

Gilead Sciences, Inc. and Merck Inc., announced that they have entered into an agreement to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen with the potential to provide new, meaningful treatment options for people living with HIV.

1 mins

News

Gilead’s lenacapavir demonstrates sustained long-acting efficacy for in heavily treated people with multi-drug resistant HIV-1 infection.

Gilead Sciences, Inc. presented additional results from the Phase II/III CAPELLA trial evaluating the company’s investigational, long-acting HIV-1 capsid inhibitor, lenacapavir, in heavily treatment-experienced people with multi-drug resistant HIV-1 infection.

4 min

News

Biktarvy shows high efficacy and durable viral suppression in treatment-naïve adults with HIV-1 in four-year data presented at CROI.- Gilead Sciences

Gilead Sciences, Inc. announced new, long-term data from open-label extensions (OLE) of two Phase III studies (Study 1489 and Study 1490) of Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF), demonstrating the sustained efficacy and safety profile and no treatment-emergent resistance with Biktarvy for the treatment of HIV-1 in treatment-naïve adults.

1 min

See all news

Related Drugs

Arsenic trioxide Mylan 1 mg/ml concentrate for solution for infusion

27 mins

Arsenic Trioxide 1 mg/ml concentrate for solution for infusion

27 mins

Anagrelide 0.5 mg Hard Capsules

17 mins

Sytron

6 mins

Pregaday 322mg / 0.35mg film-coated Tablets

6 mins

Menstralite 500 mg Tablets

3 mins

Menadiol Diphosphate 10mg Tablets

2 mins

3 mins

6 mins

8 mins

5 mins

Ferrous Sulfate Tablets BP 200mg

8 mins

Ferrous Sulfate Tablets 200mg

6 mins

Ferrous Gluconate 300mg Tablets

9 mins

Ferrous Fumarate 322mg Tablets

6 mins

Related Journals

Journal

Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report

2 mins

Journal

Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

2 mins

Journal

Distinct viral reservoirs in individuals with spontaneous control of HIV-1

1 mins

Journal

Recent Advances in the Development of Integrase Inhibitors for HIV Treatment

1 mins

Journal

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

1 mins

Journal

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection

1 mins

Journal

Advances toward Curing HIV-1 Infection in Tissue Reservoirs

1 mins

Journal

Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety

1 mins

Journal

Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients

1 mins

Journal

Dolutegravir plus lamivudine for the treatment of HIV-1 infection

1 mins

Related Guidelines

Guideline

BHIVA guidelines for the management of HIV in pregnancy and postpartum 2018 (2020 third interim update)

The overall purpose of these guidelines is to provide guidance on best clinical practice in the treatment and management of women living with HIV in the UK during pregnancy and postpartum, and their infants.

1 mins

Guideline

British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of Candidiasis 2019

The aim of the opportunistic infection guidelines is to help physicians investigate and manage people living with HIV with, or suspected of having, an opportunistic infection. They are primarily intended to guide practice in the UK and related healthcare systems.

1 min

Guideline

British HIV Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of gastrointestinal opportunistic infections 2020

Gastrointestinal (GI) symptoms occur frequently in people living with HIV. Dysphagia and diarrhoea may be caused by a wide variety of infections.

1 min

See all guidelines

Related Clinical Trials

Clinical trial

Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With Other Antiretroviral Agents in People Living With HIV (CALIBRATE)

1 mins

Clinical trial

Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With an Optimized Background Regimen in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA)

1 mins

Clinical trial

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

1 mins

Clinical trial

Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents

1 mins

Clinical trial

Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)

2 mins

Clinical trial

A Study to Investigate Different Doses of BAY1213790 to Prevent Blood Clots in Patients Undergoing Elective Total Knee Replacement Surgery (FOXTROT)

3 mins

$Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia$

Clinical trial

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

3 mins

$A Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] As Salvage Chemotherapy For Patients With Relapsed Or Refractory Aggressive Histology Non-Hodgki$

Clinical trial

A Phase III Study Of Gemcitabine, Dexamethasone, And Cisplatin Compared To Dexamethasone, Cytarabine, And Cisplatin Plus/Minus Rituximab [(R)-GDP vs (R)-DHAP] As Salvage Chemotherapy For Patients With Relapsed Or Refractory Aggressive Histology Non-Hodgki

3 mins

Clinical trial

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

3 mins

Clinical trial

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First)

3 mins

Clinical trial

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

3 mins

$Study of pomalidomide and low dose dexamethasone with or without pembrolizumab (MK-3475) in refractory or relapsed and refractory multiple myeloma (rrMM) (MK-3475-183/KEYNOTE-183)$

Clinical trial

Study of pomalidomide and low dose dexamethasone with or without pembrolizumab (MK-3475) in refractory or relapsed and refractory multiple myeloma (rrMM) (MK-3475-183/KEYNOTE-183)

2 mins